文献速递骨质疏松与代谢性骨病

骨质疏松女性起始胃抵抗型利塞膦酸与即释利塞膦酸或阿仑膦酸的骨折风险比较:美国理赔数据分析

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
PubMed 文献 · Osteoporos Int · 2023-03-06

基于美国2009至2019年理赔数据库,比较骨质疏松女性起始胃抵抗型利塞膦酸与即释利塞膦酸或阿仑膦酸后的骨折风险。调整后发生率比总体提示胃抵抗型利塞膦酸骨折风险更低,多个部位达统计学显著,尤其≥70岁女性。所有队列约40%在1年内完全停用口服双膦酸盐。

要点

  • 胃抵抗型利塞膦酸较即释利塞膦酸在盆腔骨折(全队列aIRR=0.37)等部位风险更低。
  • 胃抵抗型利塞膦酸较阿仑膦酸在盆腔骨折(全队列aIRR=0.54)等部位风险更低。
  • 所有队列约40%在治疗开始1年内完全停用口服双膦酸盐。

核心结论

  • 口服双膦酸盐治疗停药率高,但起始胃抵抗型利塞膦酸的女性多个骨骼部位骨折风险显著低于起始即释利塞膦酸或阿仑膦酸者,尤其≥70岁女性。

研究设计与样本

  • 基于美国理赔数据库(2009-2019年)的队列分析,纳入≥60岁骨质疏松女性,要求≥2次口服双膦酸盐处方配药,自首次观察到双膦酸盐配药(索引日期)后随访≥1年。
  • 比较胃抵抗型利塞膦酸队列与即释利塞膦酸或阿仑膦酸队列的骨折风险,采用调整后发生率比(aIRR),并评估所有组的双膦酸盐治疗持续性。

主要发现

  • 胃抵抗型利塞膦酸 vs 即释利塞膦酸:全队列盆腔骨折aIRR=0.37(p<0.05);≥65岁女性任何骨折aIRR=0.63、盆腔骨折aIRR=0.41;≥70岁女性任何骨折aIRR=0.69、盆腔骨折aIRR=0.24;因合并症/药物高危女性盆腔骨折aIRR=0.34。
  • 胃抵抗型利塞膦酸 vs 阿仑膦酸:全队列盆腔骨折aIRR=0.54;≥65岁女性任何骨折aIRR=0.73、腕/臂骨折aIRR=0.63;≥70岁女性任何骨折aIRR=0.72、盆腔骨折aIRR=0.36、腕/臂骨折aIRR=0.58。
  • 所有队列中约40%在1年内完全停用口服双膦酸盐。

关键数值与推荐

  • 胃抵抗型利塞膦酸 vs 即释利塞膦酸全队列盆腔骨折aIRR=0.37(p<0.05)。
  • 胃抵抗型利塞膦酸 vs 阿仑膦酸全队列盆腔骨折aIRR=0.54。
  • ≥70岁女性胃抵抗型利塞膦酸 vs 即释利塞膦酸任何骨折aIRR=0.69、盆腔骨折aIRR=0.24。
  • ≥70岁女性胃抵抗型利塞膦酸 vs 阿仑膦酸任何骨折aIRR=0.72、盆腔骨折aIRR=0.36、腕/臂骨折aIRR=0.58。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate. A large proportion of women discontinued all oral bisphosphonate therapies within 1 year of treatment start. PURPOSE: Using a US claims database (2009-2019), we compared risk of fractures between women with osteoporosis initiated on gastro-resistant (GR) risedronate and those initiated on (a) immediate release (IR) risedronate or (b) immediate release alendronate. METHODS: Women aged ≥ 60 years with osteoporosis who had ≥ 2 oral bisphosphonate prescription fills were followed for ≥ 1 year after the first observed bisphosphonates dispensing (index date). Fracture risk was compared between the GR risedronate and IR risedronate/alendronate cohorts using adjusted incidence rate ratios (aIRRs), both overall and in subgroups with high fracture risk due to older age or comorbidity/medications. Site-specific fractures were identified based on diagnosis codes recorded on medical claims using a claims-based algorithm. Persistence on bisphosphonate therapy was evaluated for all groups. RESULTS: aIRRs generally indicated lower fracture risk for GR risedronate than IR risedronate and alendronate. When comparing GR risedronate to IR risedronate, statistically significant aIRRs (p < 0.05) were observed for pelvic fractures in the full cohorts (aIRRs = 0.37), for any fracture and pelvic fractures among women aged ≥ 65 years (aIRRs = 0.63 and 0.41), for any fracture and pelvic fractures among women aged ≥ 70 years (aIRRs = 0.69 and 0.24), and for pelvic fracture among high-risk women due to comorbidity/medications (aIRR = 0.34). When comparing GR risedronate to alendronate, statistically significant aIRRs were observed for pelvic fractures in the full cohorts (aIRR = 0.54), for any fracture and wrist/arm fractures among women aged ≥ 65 years (aIRRs = 0.73 and 0.63), and for any fracture, pelvic, and wrist/arm fractures among women aged ≥ 70 years (aIRRs = 0.72, 0.36, and 0.58). In all cohorts, ~ 40% completely discontinued oral bisphosphonates within 1 year. CONCLUSIONS: Discontinuation rates of oral bisphosphonate therapy were high. However, women initiated on GR risedronate had a significantly lower risk of fracture for several skeletal sites than women initiated on IR risedronate/alendronate, particularly those aged ≥ 70 years.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Eisman JA, Cortet B, Boolell M, et al. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. Osteoporos Int. 2023. PMID: 36872338. doi:10.1007/s00198-022-06627-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。